Protagonist Therapeutics stock price
프로타고니스트 테라퓨틱스NASDAQ:PTGX · Nasdaq · HealthcareToday's signals · No active technical signal.
Signal details →Protagonist Therapeutics last closed at $140.06 (+0.63%) on 2026-10-02. Listed on Nasdaq. Trailing 12 months PER is 120.0×. Its overall grade ranks 14 of 739 stocks in Healthcare.
About this company
Protagonist Therapeutics last closed at $140.06 (+0.63%) on 2026-10-02. Listed on Nasdaq.
Details →Reported results
Position in sector
Healthcare · Overall A+ · 14/739
Valuation grade F
Related stocks
- Janssen PharmaceuticalsCustomer
PTG-300(머스타카르셉트) 상업화/라이선스 파트너로 핵심 고객 성격
- TakedaCustomer
혈액질환·염증질환 파이프라인에서 개발/상업화 파트너 관계
- Johnson & JohnsonRelated theme
염증·면역질환 대형 제약사로 Protagonist의 주요 적응증 경쟁/협업 대상
ETFs holding this stock
Invesco S&P SmallCap Health Care ETF · Neuberger Berman Disrupters ETF · Invesco S and P SmallCap Momentum ETF
Details →About Protagonist Therapeutics
- What technical signals does Protagonist Therapeutics (PTGX) have?
- Protagonist Therapeutics current technical signals: no active technical signal.
- Is Protagonist Therapeutics a cup-and-handle pattern?
- No. Protagonist Therapeutics has no valid Cup signal right now.
- What published figures are available for Protagonist Therapeutics?
- Market cap: $8.76B. Trailing 12 months PER: 120.0×. Latest quarter PBR: 11.82×. Dividend yield: 0.00%.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Major stocks in the same sector
2026-10-04 dataset
Turn what you saw on this name into a strategy
Ask Q about Protagonist Therapeutics, or open the plan table on the main site.
From the names you found, through to a scheduled run
Set the conditions and they run at the scheduled time (live orders are not open yet).